N‐terminal‐pro‐B‐type natriuretic peptide (NT‐pro‐BNP) in different thyroid function states

objective  N‐terminal B‐type natriuretic peptide (NT‐pro‐BNP) is secreted from the cardiac ventricles in response to volume expansion and pressure overload, and serum levels are elevated in systolic heart failure. The aim of this study was to evaluate the influence of thyroid function on NT‐pro‐BNP.

[1]  N. Takasu.  [Thyroid hormone and the cardiovascular system]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[2]  P. Webb,et al.  Triiodothyronine Increases Brain Natriuretic Peptide (BNP) Gene Transcription and Amplifies Endothelin-dependent BNP Gene Transcription and Hypertrophy in Neonatal Rat Ventricular Myocytes* , 2003, The Journal of Biological Chemistry.

[3]  A. Maisel.  Nesiritide: a new therapy for the treatment of heart failure. , 2003, Cardiovascular toxicology.

[4]  K. Baughman.  B-type natriuretic peptide -- a window to the heart. , 2002, The New England journal of medicine.

[5]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[6]  J. Mair.  Role of cardiac natriuretic peptide testing in heart failure. , 2002, Clinical chemistry.

[7]  L. Morrison,et al.  Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. , 2002, Journal of the American College of Cardiology.

[8]  G. Jensen,et al.  Left ventricular remodeling in the first year after acute myocardial infarction and the predictive value of N-terminal pro brain natriuretic peptide. , 2002, American heart journal.

[9]  J. Mehlsen,et al.  Hemodynamic changes after levothyroxine treatment in subclinical hypothyroidism. , 2002, Thyroid : official journal of the American Thyroid Association.

[10]  L. Morrison,et al.  Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea ☆ , 2002 .

[11]  Braham,et al.  Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure , 2002 .

[12]  J. Mehlsen,et al.  Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. , 2001, European journal of endocrinology.

[13]  J. Mair,et al.  Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[14]  R. Doughty,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 2001, Journal of the American College of Cardiology.

[15]  Michael L. Johnson,et al.  Deconvolution Analysis of Cardiac Natriuretic Peptides During Acute Volume Overload , 2000, Hypertension.

[16]  C. Frampton,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. , 1998, Circulation.

[17]  M. Emdin,et al.  Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure , 1998, Journal of endocrinological investigation.

[18]  D. A. Meier.  Werner and Ingbar's The Thyroid , 1997 .

[19]  R. Doughty,et al.  Immunoreactive amino‐terminal pro‐brain natriuretic peptide (NT‐PROBNP): a new marker of cardiac impairment , 1997, Clinical endocrinology.

[20]  D. Fukai,et al.  Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. , 1997, Circulation.

[21]  N. Iwai,et al.  DIFFERENTIAL REGULATION OF NATRIURETIC PEPTIDE GENES IN INFARCTED RAT HEARTS , 1997, Clinical and experimental pharmacology & physiology.

[22]  K. Nakao,et al.  Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. , 1995, The Journal of clinical investigation.

[23]  A. Galløe,et al.  Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. , 1994, European journal of endocrinology.

[24]  T. Horio,et al.  Stimulation of brain natriuretic peptide release from the heart by thyroid hormone. , 1993, Metabolism: clinical and experimental.

[25]  J. Mehlsen,et al.  Reliability of impedance cardiography in measuring central haemodynamics. , 1991, Clinical physiology.

[26]  D. Iannone.  [The cardiovascular system in hypothyroidism]. , 1967, Il Policlinico. Sezione pratica.

[27]  T. Lynn.  The cardiovascular system in thyrotoxicosis. , 1961, The Journal of the Oklahoma State Medical Association.